Array BioPharma
E474928
Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
Statements (44)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
public company ⓘ |
| acquiredBy | Pfizer NERFINISHED ⓘ |
| acquisitionDate | 2019 ⓘ |
| collaboratedWith |
AstraZeneca
NERFINISHED
ⓘ
Celgene NERFINISHED ⓘ Novartis NERFINISHED ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| developed |
binimetinib
NERFINISHED
ⓘ
encorafenib ⓘ |
| develops | small-molecule cancer therapies ⓘ |
| employs |
scientists specializing in medicinal chemistry
ⓘ
scientists specializing in oncology drug development ⓘ |
| focusesOn |
oncology
ⓘ
rare diseases ⓘ targeted small-molecule therapies ⓘ |
| foundedIn | 1998 ⓘ |
| hasIndication |
BRAF V600E-mutant colorectal cancer
ⓘ
BRAF-mutant melanoma ⓘ |
| hasPipeline |
early-stage oncology programs
ⓘ
late-stage oncology programs ⓘ |
| hasTherapy |
BRAF inhibitor encorafenib
NERFINISHED
ⓘ
MEK inhibitor binimetinib NERFINISHED ⓘ binimetinib NERFINISHED ⓘ encorafenib NERFINISHED ⓘ |
| headquartersLocation | Boulder, Colorado NERFINISHED ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| knownFor | targeted cancer therapies ⓘ |
| parentCompany | Pfizer NERFINISHED ⓘ |
| productType | oral small-molecule drugs ⓘ |
| regulatoryApproval |
FDA approval for encorafenib and binimetinib combination in melanoma
ⓘ
FDA approval for encorafenib in BRAF V600E-mutant metastatic colorectal cancer ⓘ |
| researchFocus |
kinase inhibitors
ⓘ
signal transduction pathways ⓘ |
| specializesIn |
BRAF inhibitors
ⓘ
MEK inhibitors ⓘ |
| state | Colorado ⓘ |
| status | subsidiary of Pfizer ⓘ |
| stockExchange | NASDAQ ⓘ |
| therapeuticArea |
colorectal cancer
ⓘ
melanoma ⓘ solid tumors ⓘ |
| tickerSymbol | ARRY NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.